السوق العالمية لعلاجات سرطان الثدي الإيجابي لمستقبلات HER2 - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER'S 5 FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

5.1 DIAGNOSED INCIDENT CASES OF ALL INVASIVE BREAST CANCER

5.2 AGE-SPECIFIC DIAGNOSED INCIDENT CASES OF ALL INVASIVE BREAST CANCER

5.3 TREATMENT RATE

5.4 MORTALITY RATE

5.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL

5.6 PATEINT TREATMENT SUCCESS RATES

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH OCBOLOGIST

6.8 INTERVIEWS WITH RESEARCHERS

6.9 OTHER KOL SNAPSHOTS

7 REGULATORY SCENARIO

7.1 FDA APPROVALS

7.2 EMA APPROVALS

8 MERGERS AND ACQUISITION

8.1 LICENSING

8.2 COMMERCIALIZATION AGREEMENTS

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

10 MARKET OVERVIEW

10.1 DRIVERS

10.2 RESTRAINS

10.3 OPPURTUNITY

10.4 CHALLENGES

11 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 CHEMOTHERAPY

11.2.1 TAXANES

11.2.1.1. BY DRUGS

11.2.1.1.1. PACLITAXEL

11.2.1.1.1.1 MARKET VALUE (USD MN)

11.2.1.1.1.2 MARKET VOLUME (IU)

11.2.1.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.1.1.2. DOCETAXEL

11.2.1.1.2.1 MARKET VALUE (USD MN)

11.2.1.1.2.2 MARKET VOLUME (IU)

11.2.1.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.1.1.3. ALBUMIN BOUND PACLITAXEL

11.2.1.1.3.1 MARKET VALUE (USD MN)

11.2.1.1.3.2 MARKET VOLUME (IU)

11.2.1.1.3.3 AVERAGE SELLING PRICE (USD)

11.2.1.1.4. OTHERS

11.2.1.2. BY DRUG TYPE

11.2.1.2.1. GENERICS

11.2.1.2.1.1 MARKET VALUE (USD MN)

11.2.1.2.1.2 MARKET VOLUME (IU)

11.2.1.2.1.3 AVERAGE SELLING PRICE (USD)

11.2.1.2.2. BRANDED

11.2.1.2.2.1 MARKET VALUE (USD MN)

11.2.1.2.2.2 MARKET VOLUME (IU)

11.2.1.2.2.3 AVERAGE SELLING PRICE (USD)

11.2.2 ANTHRACYCLINES

11.2.2.1. BY TYPE

11.2.2.1.1. DOXORUBICIN

11.2.2.1.1.1 MARKET VALUE (USD MN)

11.2.2.1.1.2 MARKET VOLUME (IU)

11.2.2.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.2.1.2. LIPOSOMAL DOXORUBICIN

11.2.2.1.2.1 MARKET VALUE (USD MN)

11.2.2.1.2.2 MARKET VOLUME (IU)

11.2.2.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.2.1.3. EPIRUBICIN

11.2.2.1.3.1 MARKET VALUE (USD MN)

11.2.2.1.3.2 MARKET VOLUME (IU)

11.2.2.1.3.3 AVERAGE SELLING PRICE (USD)

11.2.2.1.4. OTHERS

11.2.2.2. BY DRUG TYPE

11.2.2.2.1. GENERICS

11.2.2.2.1.1 MARKET VALUE (USD MN)

11.2.2.2.1.2 MARKET VOLUME (IU)

11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.2.2.2.2. BRANDED

11.2.2.2.2.1 MARKET VALUE (USD MN)

11.2.2.2.2.2 MARKET VOLUME (IU)

11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.2.3 PLATINUM AGENTS

11.2.3.1. BY TYPE

11.2.3.1.1. CISPLATIN

11.2.3.1.1.1 MARKET VALUE (USD MN)

11.2.3.1.1.2 MARKET VOLUME (IU)

11.2.3.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.3.1.2. CARBOPLATIN

11.2.3.1.2.1 MARKET VALUE (USD MN)

11.2.3.1.2.2 MARKET VOLUME (IU)

11.2.3.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.3.1.3. OTHERS

11.2.3.2. BY DRUG TYPE

11.2.3.2.1. GENERICS

11.2.3.2.1.1 MARKET VALUE (USD MN)

11.2.3.2.1.2 MARKET VOLUME (IU)

11.2.3.2.1.3 AVERAGE SELLING PRICE (USD)

11.2.3.2.2. BRANDED

11.2.3.2.2.1 MARKET VALUE (USD MN)

11.2.3.2.2.2 MARKET VOLUME (IU)

11.2.3.2.2.3 AVERAGE SELLING PRICE (USD)

11.2.4 ANTIMETABOLITES

11.2.4.1. BY TYPE

11.2.4.1.1. CAPECITABINE

11.2.4.1.1.1 MARKET VALUE (USD MN)

11.2.4.1.1.2 MARKET VOLUME (IU)

11.2.4.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.4.1.2. GEMCITABINE

11.2.4.1.2.1 MARKET VALUE (USD MN)

11.2.4.1.2.2 MARKET VOLUME (IU)

11.2.4.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.4.2. BY DRUG TYPE

11.2.4.2.1. GENERICS

11.2.4.2.1.1 MARKET VALUE (USD MN)

11.2.4.2.1.2 MARKET VOLUME (IU)

11.2.4.2.1.3 AVERAGE SELLING PRICE (USD)

11.2.4.2.2. BRANDED

11.2.4.2.2.1 MARKET VALUE (USD MN)

11.2.4.2.2.2 MARKET VOLUME (IU)

11.2.4.2.2.3 AVERAGE SELLING PRICE (USD)

11.2.5 MICROTUBULE INHIBITORS

11.2.5.1. BY TYPE

11.2.5.1.1. IXABEPILONE

11.2.5.1.1.1 MARKET VALUE (USD MN)

11.2.5.1.1.2 MARKET VOLUME (IU)

11.2.5.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.5.1.2. ERBULIN

11.2.5.1.2.1 MARKET VALUE (USD MN)

11.2.5.1.2.2 MARKET VOLUME (IU)

11.2.5.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.5.1.3. OTHERS

11.2.5.2. BY DRUG TYPE

11.2.5.2.1. GENERICS

11.2.5.2.1.1 MARKET VALUE (USD MN)

11.2.5.2.1.2 MARKET VOLUME (IU)

11.2.5.2.1.3 AVERAGE SELLING PRICE (USD)

11.2.5.2.2. BRANDED

11.2.5.2.2.1 MARKET VALUE (USD MN)

11.2.5.2.2.2 MARKET VOLUME (IU)

11.2.5.2.2.3 AVERAGE SELLING PRICE (USD)

11.3 TARGETED DRUG THERAPY

11.3.1 MONOCLONAL ANTIBODIES

11.3.1.1. BY TYPE

11.3.1.1.1. TRASTUZUMAB

11.3.1.1.1.1 MARKET VALUE (USD MN)

11.3.1.1.1.2 MARKET VOLUME (IU)

11.3.1.1.1.3 AVERAGE SELLING PRICE (USD)

11.3.1.1.2. PERTUZUMAB

11.3.1.1.2.1 MARKET VALUE (USD MN)

11.3.1.1.2.2 MARKET VOLUME (IU)

11.3.1.1.2.3 AVERAGE SELLING PRICE (USD)

11.3.1.1.3. TRASTUZUMAB, PERTUZUMAB, AND HYALURONIDASE INJECTION (COMBINATION DRUGS)

11.3.1.1.3.1 MARKET VALUE (USD MN)

11.3.1.1.3.2 MARKET VOLUME (IU)

11.3.1.1.3.3 AVERAGE SELLING PRICE (USD)

11.3.1.1.4. MARGETUXIMAB

11.3.1.1.4.1 MARKET VALUE (USD MN)

11.3.1.1.4.2 MARKET VOLUME (IU)

11.3.1.1.4.3 AVERAGE SELLING PRICE (USD)

11.3.1.1.5. OTHERS

11.3.1.2. BY DRUG TYPE

11.3.1.2.1. BIOLOGICS

11.3.1.2.1.1 MARKET VALUE (USD MN)

11.3.1.2.1.2 MARKET VOLUME (IU)

11.3.1.2.1.3 AVERAGE SELLING PRICE (USD)

11.3.1.2.2. BIOSIMILAR

11.3.1.2.2.1 MARKET VALUE (USD MN)

11.3.1.2.2.2 MARKET VOLUME (IU)

11.3.1.2.2.3 AVERAGE SELLING PRICE (USD)

11.3.2 KINASE INHIBITORS

11.3.2.1. BY TYPE

11.3.2.1.1. TUCATINIB

11.3.2.1.1.1 MARKET VALUE (USD MN)

11.3.2.1.1.2 MARKET VOLUME (IU)

11.3.2.1.1.3 AVERAGE SELLING PRICE (USD)

11.3.2.1.2. LAPATINIB

11.3.2.1.2.1 MARKET VALUE (USD MN)

11.3.2.1.2.2 MARKET VOLUME (IU)

11.3.2.1.2.3 AVERAGE SELLING PRICE (USD)

11.3.2.1.3. NERTINIB

11.3.2.1.3.1 MARKET VALUE (USD MN)

11.3.2.1.3.2 MARKET VOLUME (IU)

11.3.2.1.3.3 AVERAGE SELLING PRICE (USD)

11.3.2.2. BY DRUG TYPE

11.3.2.2.1. GENERICS

11.3.2.2.1.1 MARKET VALUE (USD MN)

11.3.2.2.1.2 MARKET VOLUME (IU)

11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)

11.3.2.2.2. BRANDED

11.3.2.2.2.1 MARKET VALUE (USD MN)

11.3.2.2.2.2 MARKET VOLUME (IU)

11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)

11.3.3 ANTIBODY DRUG CONJUGATES

11.3.3.1. ADO-TRASTUZUMAB EMTANSINE

11.3.3.1.1. MARKET VALUE (USD MN)

11.3.3.1.2. MARKET VOLUME (IU)

11.3.3.1.3. AVERAGE SELLING PRICE (USD)

11.3.3.2. FAM-TRASTUZUMAB DERUXTECAN

11.3.3.2.1. MARKET VALUE (USD MN)

11.3.3.2.2. MARKET VOLUME (IU)

11.3.3.2.3. AVERAGE SELLING PRICE (USD)

11.3.3.3. OTHERS

11.4 HORMONE THERAPY

11.4.1 BY TYPE

11.4.1.1. TAMOXIFEN

11.4.1.1.1. MARKET VALUE (USD MN)

11.4.1.1.2. MARKET VOLUME (IU)

11.4.1.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.2. TOREMIFENE

11.4.1.2.1. MARKET VALUE (USD MN)

11.4.1.2.2. MARKET VOLUME (IU)

11.4.1.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.3. FULVESTRANT

11.4.1.3.1. MARKET VALUE (USD MN)

11.4.1.3.2. MARKET VOLUME (IU)

11.4.1.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.4. OTHERS

11.4.2 BY DRUG TYPE

11.4.2.1. GENERICS

11.4.2.1.1. MARKET VALUE (USD MN)

11.4.2.1.2. MARKET VOLUME (IU)

11.4.2.1.3. AVERAGE SELLING PRICE (USD)

11.4.2.2. BRANDED

11.4.2.2.1. MARKET VALUE (USD MN)

11.4.2.2.2. MARKET VOLUME (IU)

11.4.2.2.3. AVERAGE SELLING PRICE (USD)

11.5 OTHERS

11.5.1 RADIATION THERAPY

11.5.2 SURGERY

11.5.3 RECONSTRUCTIVE SURGERY

12 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY USAGE TYPE

12.1 NEOADJUVENT USE

12.2 ADJUVANT USE

13 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY STAGES

13.1 STAGE 0

13.2 STAGE I

13.3 STAGE II

13.4 STAGE III

13.5 STAGE IV

14 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY AGE GROUP

14.1 OVERVIEW

14.2 BELOW 30 YEARS

14.3 30-50 YEARS

14.4 ABOVE 50 YEARS

15 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

15.1 OVERVIEW

15.2 ORAL

15.3 PARENTERAL

15.4 OTHERS

16 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.3 SPECIALTY CLINICS

16.4 ACADEMIC AND RESEARCH INSTITUTES

16.5 OTHERS

17 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 HOSPITAL PHARMACY

17.3 RETAIL PHARMACY

17.4 ONLINE PHARMACY

17.5 OTHERS

18 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY GEOGRAPHY

18.1 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

18.2 NORTH AMERICA

18.2.1 U.S.

18.2.1.1. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY TREATMENT

18.2.1.2. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY USAGE TYPE

18.2.1.3. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY STAGES

18.2.1.4. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY AGE GROUP

18.2.1.5. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

18.2.1.6. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY END USER

18.2.1.7. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

18.2.1.8. CANADA

18.2.1.9. MEXICO

18.2.2 EUROPE

18.2.2.1. GERMANY

18.2.2.2. FRANCE

18.2.2.3. U.K.

18.2.2.4. ITALY

18.2.2.5. SPAIN

18.2.2.6. RUSSIA

18.2.2.7. TURKEY

18.2.2.8. BELGIUM

18.2.2.9. DENMARK

18.2.2.10. SWEDEN

18.2.2.11. POLAND

18.2.2.12. NORWAY

18.2.2.13. FINLAND

18.2.2.14. NETHERLANDS

18.2.2.15. SWITZERLAND

18.2.2.16. REST OF EUROPE

18.2.3 ASIA-PACIFIC

18.2.3.1. JAPAN

18.2.3.2. CHINA

18.2.3.3. SOUTH KOREA

18.2.3.4. INDIA

18.2.3.5. AUSTRALIA

18.2.3.6. SINGAPORE

18.2.3.7. THAILAND

18.2.3.8. MALAYSIA

18.2.3.9. INDONESIA

18.2.3.10. PHILIPPINES

18.2.3.11. TAIWAN

18.2.3.12. INDONESIA

18.2.3.13. VIETNAM

18.2.3.14. REST OF ASIA-PACIFIC

18.2.4 SOUTH AMERICA

18.2.4.1. BRAZIL

18.2.4.2. ARGENTINA

18.2.4.3. REST OF SOUTH AMERICA

18.2.5 MIDDLE EAST AND AFRICA

18.2.5.1. SOUTH AFRICA

18.2.5.2. SAUDI ARABIA

18.2.5.3. UAE

18.2.5.4. EGYPT

18.2.5.5. BAHRAIN

18.2.5.6. KUWAIT

18.2.5.7. QATAR

18.2.5.8. OMAN

18.2.5.9. ISRAEL

18.2.5.10. REST OF MIDDLE EAST AND AFRICA

19 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, SWOT AND DBMR ANALYSIS

20 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: GLOBAL

20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

20.3 COMPANY SHARE ANALYSIS: EUROPE

20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20.5 MERGERS & ACQUISITIONS

20.6 NEW PRODUCT DEVELOPMENT & APPROVALS

20.7 EXPANSIONS

20.8 REGULATORY CHANGES

20.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

21 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, COMPANY PROFILE

21.1 ASTRAZENCA

21.1.1 COMPANY OVERVIEW

21.1.2 REVENUE ANALYSIS

21.1.3 GEOGRAPHIC PRESENCE

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENTS

21.2 DAIICHI SANKYO

21.2.1 COMPANY OVERVIEW

21.2.2 REVENUE ANALYSIS

21.2.3 GEOGRAPHIC PRESENCE

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 BRISTOL MEYERS SQUIBB

21.3.1 COMPANY OVERVIEW

21.3.2 REVENUE ANALYSIS

21.3.3 GEOGRAPHIC PRESENCE

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENTS

21.4 EISAI INC

21.4.1 COMPANY OVERVIEW

21.4.2 REVENUE ANALYSIS

21.4.3 GEOGRAPHIC PRESENCE

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENTS

21.5 F-HOFFMANN LA ROCHE

21.5.1 COMPANY OVERVIEW

21.5.2 REVENUE ANALYSIS

21.5.3 GEOGRAPHIC PRESENCE

21.5.4 PRODUCT PORTFOLIO

21.5.5 RECENT DEVELOPMENTS

21.6 GSK

21.6.1 COMPANY OVERVIEW

21.6.2 REVENUE ANALYSIS

21.6.3 GEOGRAPHIC PRESENCE

21.6.4 PRODUCT PORTFOLIO

21.6.5 RECENT DEVELOPMENTS

21.7 GENETECH

21.7.1 COMPANY OVERVIEW

21.7.2 REVENUE ANALYSIS

21.7.3 GEOGRAPHIC PRESENCE

21.7.4 PRODUCT PORTFOLIO

21.7.5 RECENT DEVELOPMENTS

21.8 PFIZER

21.8.1 COMPANY OVERVIEW

21.8.2 REVENUE ANALYSIS

21.8.3 GEOGRAPHIC PRESENCE

21.8.4 PRODUCT PORTFOLIO

21.8.5 RECENT DEVELOPMENTS

21.9 MERCK & CO, INC

21.9.1 COMPANY OVERVIEW

21.9.2 REVENUE ANALYSIS

21.9.3 GEOGRAPHIC PRESENCE

21.9.4 PRODUCT PORTFOLIO

21.9.5 RECENT DEVELOPMENTS

21.1 PUMA BIOTECHNOLOGY INC

21.10.1 COMPANY OVERVIEW

21.10.2 REVENUE ANALYSIS

21.10.3 GEOGRAPHIC PRESENCE

21.10.4 PRODUCT PORTFOLIO

21.10.5 RECENT DEVELOPMENTS

21.11 ELI LILLY

21.11.1 COMPANY OVERVIEW

21.11.2 REVENUE ANALYSIS

21.11.3 GEOGRAPHIC PRESENCE

21.11.4 PRODUCT PORTFOLIO

21.11.5 RECENT DEVELOPMENTS

21.12 CELLTRION

21.12.1 COMPANY OVERVIEW

21.12.2 REVENUE ANALYSIS

21.12.3 GEOGRAPHIC PRESENCE

21.12.4 PRODUCT PORTFOLIO

21.12.5 RECENT DEVELOPMENTS

21.13 GILEAD SVIENCES

21.13.1 COMPANY OVERVIEW

21.13.2 REVENUE ANALYSIS

21.13.3 GEOGRAPHIC PRESENCE

21.13.4 PRODUCT PORTFOLIO

21.13.5 RECENT DEVELOPMENTS

21.14 AMGEN

21.14.1 COMPANY OVERVIEW

21.14.2 REVENUE ANALYSIS

21.14.3 GEOGRAPHIC PRESENCE

21.14.4 PRODUCT PORTFOLIO

21.14.5 RECENT DEVELOPMENTS

21.15 DR REDDY LABORATORIES

21.15.1 COMPANY OVERVIEW

21.15.2 REVENUE ANALYSIS

21.15.3 GEOGRAPHIC PRESENCE

21.15.4 PRODUCT PORTFOLIO

21.15.5 RECENT DEVELOPMENTS

21.16 MYLAN PHARMACEUTICALS

21.16.1 COMPANY OVERVIEW

21.16.2 REVENUE ANALYSIS

21.16.3 GEOGRAPHIC PRESENCE

21.16.4 PRODUCT PORTFOLIO

21.16.5 RECENT DEVELOPMENTS

21.17 KYOWA KRIN INTERNATIONAL

21.17.1 COMPANY OVERVIEW

21.17.2 REVENUE ANALYSIS

21.17.3 GEOGRAPHIC PRESENCE

21.17.4 PRODUCT PORTFOLIO

21.17.5 RECENT DEVELOPMENTS

21.18 JOHNSONS & JOHNSON (JANSSEN PHARMACEUTICASL)

21.18.1 COMPANY OVERVIEW

21.18.2 REVENUE ANALYSIS

21.18.3 GEOGRAPHIC PRESENCE

21.18.4 PRODUCT PORTFOLIO

21.18.5 RECENT DEVELOPMENTS

21.19 BAXTER HEALTHCARE

21.19.1 COMPANY OVERVIEW

21.19.2 REVENUE ANALYSIS

21.19.3 GEOGRAPHIC PRESENCE

21.19.4 PRODUCT PORTFOLIO

21.19.5 RECENT DEVELOPMENTS

21.2 AMNEAL PHARMACEUTICALS

21.20.1 COMPANY OVERVIEW

21.20.2 REVENUE ANALYSIS

21.20.3 GEOGRAPHIC PRESENCE

21.20.4 PRODUCT PORTFOLIO

21.20.5 RECENT DEVELOPMENTS

21.21 ABBOTT LABORATORIES

21.21.1 COMPANY OVERVIEW

21.21.2 REVENUE ANALYSIS

21.21.3 GEOGRAPHIC PRESENCE

21.21.4 PRODUCT PORTFOLIO

21.21.5 RECENT DEVELOPMENTS

21.22 ABBVIE INC

21.22.1 COMPANY OVERVIEW

21.22.2 REVENUE ANALYSIS

21.22.3 GEOGRAPHIC PRESENCE

21.22.4 PRODUCT PORTFOLIO

21.22.5 RECENT DEVELOPMENTS

21.23 NOVARTIS AG

21.23.1 COMPANY OVERVIEW

21.23.2 REVENUE ANALYSIS

21.23.3 GEOGRAPHIC PRESENCE

21.23.4 PRODUCT PORTFOLIO

21.23.5 RECENT DEVELOPMENTS

21.24 TEVA PHARMACEUTICALS

21.24.1 COMPANY OVERVIEW

21.24.2 REVENUE ANALYSIS

21.24.3 GEOGRAPHIC PRESENCE

21.24.4 PRODUCT PORTFOLIO

21.24.5 RECENT DEVELOPMENTS

21.25 APOTEX CORPORATION

21.25.1 COMPANY OVERVIEW

21.25.2 REVENUE ANALYSIS

21.25.3 GEOGRAPHIC PRESENCE

21.25.4 PRODUCT PORTFOLIO

21.25.5 RECENT DEVELOPMENTS

*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

22 RELATED REPORTS

23 CONCLUSION

24 QUESTIONNAIRE

25 ABOUT DATA BRIDGE MARKET RESEARCH